# A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

> **NCT07282574** · PHASE2 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 360 (estimated)

## Conditions studied

- Progressive Multiple Sclerosis

## Interventions

- **DRUG:** RO7268489
- **DRUG:** Ocrelizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07282574
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-10
- **Primary completion:** 2028-05-30
- **Final completion:** 2030-05-30
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07282574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07282574, "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07282574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*